Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load

Fujiwara, Kenji; Kaneko, Shuichi; Kakumu, Shinichi; Sata, Michio; Hige, Shuhei; Tomita, Eiichi; Mochida, Satoshi

doi:10.1111/j.1872-034x.2007.00117.x

Cited by 49 publications

(61 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported the use of DFPP for HCV treatment [4][5][6]. Fujiwara et al [4] demonstrated that DFPP plus IFN combination therapy produced a considerable reduction in the viral load during the early stage of treatment and yielded a high SVR rate.…”

Section: Discussionmentioning

confidence: 99%

“…Fujiwara et al [4] demonstrated that DFPP plus IFN combination therapy produced a considerable reduction in the viral load during the early stage of treatment and yielded a high SVR rate. Subsequently, Namba et al [5] also reported the use of DFPP plus IFN combination therapy to reduce HCV RNA blood levels in the early stage of IFN therapy.…”

Section: Discussionmentioning

confidence: 99%

“…VRAD therapy was administered as described previously [4][5][6]. A Plasmaflo TM OP-08W (Asahi Kasei Medical) and an Evaflux TM 5A20 (Asahi Kasei Medical) were used as the plasma separator (first filter) and plasma fractionator (second filter), respectively.…”

Section: Case Reportmentioning

confidence: 99%

“…However, published case reports and uncontrolled studies have only included a small number of patients, and the results have been controversial [3]. In a recent Japanese study [4], double-filtration plasmapheresis (DFPP) was used as antiviral treatment with IFN and ribavirin for chronic hepatitis C patients, and significantly higher reductions in viral load and better sustained virological response (SVR) rates were achieved compared with a non-DFPP group. Moreover, in a case of HCV-related glomerulonephritis, this combination therapy reduced viral load and thereby induced clinical remission of MPGN [5].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

et al. 2014

View full text Add to dashboard Cite

A 66-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital with oliguria, systemic edema, and rapid deterioration of renal function. Laboratory examination showed increased serum creatinine and decreased serum albumin levels, complement activity, and cryoglobulin positivity. The HCV RNA genotype was found to be 1b, and the viral load was high. Kidney biopsy examination showed type I membranoproliferative glomerulonephritis with capillary deposition of IgM and C3, indicating HCV-related glomerulonephritis. After hospitalization, hemodialysis was immediately required because of uremia and oliguria. Her renal function did not improve despite corticosteroid therapy. To treat the increasing HCV load, virus removal and eradication by double-filtration plasmapheresis therapy without interferon was performed, since the patient was allergic to interferon therapy. This treatment improved renal function and allowed the withdrawal from hemodialysis. This report presents a case of successful VRAD without interferon therapy in a patient with HCV-related glomerulonephritis and acute kidney injury that required hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Case Reportmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Combination of DFPP and IFN also achieved impressive SVR in difficult-to-treat patients (i.e., relapsed, nonresponder, or HIVcoinfected patients) [181][182][183][184] and may also be safe for the elderly population [185]. However, the approach of apheresis for decreasing HCV viral load requires specialty equipment and possesses potential risk of adverse events (e.g., blood pressure lowering, puncture site hematoma, or infection) [181,185].…”

Section: Therapeutic Apheresis For the Removal Of Hcv Virionsmentioning

confidence: 99%

Strategies to Preclude Hepatitis C Virus Entry

Burnouf¹,

Lin²

2017

Advances in Treatment of Hepatitis C and B

View full text Add to dashboard Cite

Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

show abstract

Double‐filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia

Ramunni

Lauletta

Brescia

et al. 2008

J of Clinical Apheresis

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is the major cause of cryoglobulinemia. Skin lesions are frequent and can be cured from the removal of cryoglobulins by therapeutic apheresis. We describe a case of HCV-positive type I cryoglobulinemia with severe leg ulcers, not responsive to antiviral and immunosuppressive treatment. Thirty sessions of double filtration plasmapheresis were performed, over a period of 6 months, with no other associated treatment. Before and after each session an assessment of immunoglobulins, complement, cryocrit, and fibrinogen was made. HCV RNA levels were determined in serum cryoprecipitate, supernatant before and after each session, and in the collection bag. No differences in pre and postapheresis values were observed in the serum concentrations and the supernatant, whereas the postapheresis cryoprecipitate showed a significantly reduced viral load (P < 0.02) as compared with the preapheresis values. There was improvement in the condition of ulcers in the leg during apheresis and had completely regressed by the end of the cycle.

show abstract

Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load

Abstract: DFPP plus IFN combination therapy produced a great reduction of viral load during the early stage of treatment and achieved a high sustained virus response, suggesting that this combination therapy may be a new modality for chronic hepatitis C patients at difficult-to-treat states.

Cited by 49 publications

References 31 publications

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

Strategies to Preclude Hepatitis C Virus Entry

Double‐filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia

Contact Info

Product

Resources

About